Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.

ABSTRACT:

Importance

Outcomes of treating high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, remain uncertain. Emerging evidence shows that post HSIL treatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves the effectiveness of treatment. However, no recommendations exist regarding the use of qHPV vaccine as an adjuvant form of therapy. Our objective was to determine whether post-treatment adjuvant vaccination should be adopted in HIV-infected MSM (individuals at highest risk for anal cancer) on the basis of cost-effectiveness determined using existing evidence or whether future research is needed.

Methods

We developed a Markov (state-transition) cohort model to assess the cost-effectiveness of post-treatment adjuvant HPV vaccinatio

SUBMITTER: Deshmukh AA 

PROVIDER: S-EPMC5581672 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature